CyFlow™ CD18 FITC

CyFlow™ CD18 FITC
Laser: Blue
Target Species: Mouse
Antigen: CD18
Field of Interest: Immunophenotyping, MHC
Clone: M18/2
Regulatory Status: RUO
Alternative Name: b2 integrin
Application: Flow cytometry
Format/Fluorochrome: FITC
Species of Origin: Rat
Clonality: monoclonal
Emission Maximum: 518 nm
Excitation Maximum: 490 to 495 nm
Isotype: IgG2a
Product number: AQ070678

For Research Use Only

$235.00 USD*

Price excludes any applicable taxes plus shipping costs

Concentration 0.5 mg/mL Quantity 0.1 mg Volume 0.2 mL Immunogen Mouse cytotoxic T... more
CyFlow™ CD18 FITC
Concentration0.5 mg/mL
Quantity0.1 mg
Volume0.2 mL
ImmunogenMouse cytotoxic T cell glycoproteins
Background InformationCD18 (integrin β2 subunit) forms heterodimers with four types of CD11 molecule to constitute leukocyte (β2) integrins: αLβ2 (CD11a/CD18, LFA-1), αMβ2 (CD11b/CD18, Mac-1, CR3), αXβ2 (CD11c/CD18) and αDβ2 (CD11d/CD18). In most cases, the response mediated by the integrin is a composite of the functions of its individual subunits. These integrins are essential for proper leukocyte migration, mediating intercellular contacts.
UsageThe reagent is designed for Flow Cytometry analysis. Suggested working usage is 3·µg/ml. Indicated dilution is recommended starting point for use of this product, but working concentrations should be validated by the investigator.
Storage BufferThe reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide.
StorageAvoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
StabilityDo not use after expiration date stamped on vial label.

Specific References

| Sanchez-Madrid F, Simon P, Thompson S, Springer TA: Mapping of antigenic and functional epitopes on the alpha‑ and beta‑subunits of two related mouse glycoproteins involved in cell interactions, LFA‑1 and Mac‑1. J·Exp·Med. 1983·Aug·1; 158(2):586‑602. <·PMID:·6193226·> | Zahalka MA, Okon E, Naor D: Blocking lymphoma invasiveness with a monoclonal antibody directed against the beta‑chain of the leukocyte adhesion molecule (CD18). J·Immunol. 1993·May·15; 150(10):4466‑77. <·PMID:·8097756·> | Zahalka MA, Naor D: Beta 2‑integrin dependent aggregate formation between LB T cell lymphoma and spleen cells: assessment of correlation with spleen invasiveness. Int·Immunol. 1994·Jun; 6(6):917‑24. <·PMID:·7522049·> | Avni O, Pur Z, Yefenof E, Baniyash M: Complement receptor 3 of macrophages is associated with galectin‑1‑like protein. J·Immunol. 1998·Jun·15; 160(12):6151‑8. <·PMID:·9637533·> | Abraham C, Miller J: Molecular mechanisms of IL‑2 gene regulation following costimulation through LFA‑1. J·Immunol. 2001·Nov·1; 167(9):5193‑201. <·PMID:·11673532·> | Sakurai E, Taguchi H, Anand A, Ambati BK, Gragoudas ES, Miller JW, Adamis AP, Ambati J: Targeted disruption of the CD18 or ICAM‑1 gene inhibits choroidal neovascularization. Invest·Ophthalmol·Vis·Sci. 2003·Jun; 44(6):2743‑9. <·PMID:·12766082·> | Barlow SC, Langston W, Matthews KM, Chidlow JH Jr, Kevil CG: CD18 deficiency protects against multiple low‑dose streptozotocin‑induced diabetes. Am·J·Pathol. 2004·Dec; 165(6):1849‑52. <·PMID:·15579429·> | Watts GM, Beurskens FJ, Martin-Padura I, Ballantyne CM, Klickstein LB, Brenner MB, Lee DM: Manifestations of inflammatory arthritis are critically dependent on LFA‑1. J·Immunol. 2005·Mar·15; 174(6):3668‑75. <·PMID:·15749905·> | Varga G, Balkow S, Wild MK, Stadtbaeumer A, Krummen M, Rothoeft T, Higuchi T, Beissert S, Wethmar K, Scharffetter-Kochanek K, Vestweber D, Grabbe S: Active MAC‑1 (CD11b/CD18) on DCs inhibits full T‑cell activation. Blood. 2007·Jan·15; 109(2):661‑9. <·PMID:·17003381·> | Cullere X, Lauterbach M, Tsuboi N, Mayadas TN: Neutrophil‑selective CD18 silencing using RNA interference in vivo. Blood. 2008·Apr·1; 111(7):3591‑8. <·PMID:·18216298·>

Article successfully added.